Chemotherapy for advanced non-small-cell lung cancer.
The management of patients with advanced non-small-cell lung cancer has changed considerably in the last decade. Chemotherapy prolongs survival and improves quality of life in patients with a good performance status and appears to improve disease-related symptoms in patients with a lower performance status. Platinum-based doublets remain the standard regimen, but nonplatinum combinations are reasonable alternatives. Newer agents with novel mechanisms of action have opened new areas of clinical research and are likely to further improve the outcome of patients with advanced non-small-cell lung cancer.
Raez
Luis E
LE
Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL 33136, USA.
Lilenbaum
Rogerio
R
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006133:Growth Substances / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D011379:Prognosis
D000911:Antibodies, Monoclonal; D016861:Cyclooxygenase Inhibitors; D004791:Enzyme Inhibitors; D006133:Growth Substances; D016376:Oligonucleotides, Antisense